Takeda Pharmaceutical - Positive Results From Two Pivotal Phase 3 Studies Of Oveporexton (Tak-861) In Narcolepsy Type 1
RefinitivBacaan kurang dari 1 minit
Takeda Pharmaceutical Co Ltd 4502:
ANNOUNCES POSITIVE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF OVEPOREXTON (TAK-861) IN NARCOLEPSY TYPE 1
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini